The cost-effectiveness of pneumococcal vaccination in healthy adults over 50: An exploration of influential factors for Belgium
详细信息 查看全文
- 作者：Adriaan Blommaerta ; b ; adriaan.blommaert@uantwerp.be" class="auth_mail" title="E-mail the corresponding author ; Joke Bilckea ; Lander Willema ; b ; c ; Jan Verhaegend ; Herman Goossense ; Philippe Beutelsa ; f
- 关键词：00-01 ; 99-00
- 刊名：Vaccine
- 出版年：2016
- 出版时间：19 April 2016
- 年：2016
- 卷：34
- 期：18
- 页码：2106-2112
- 全文大小：545 K
文摘
- •
At current prices, pneumococcal vaccination in healthy elderly is unlikely cost-effective.
- •
With similar duration of protection, PPV23 dominates PCV13 through lower price.
- •
Duration of vaccine protection is the key uncertain factor.
- •
Serotype distribution changes through childhood vaccination are highly influential.